Eisai, Novarti Sign Commercial Pact for Cancer DrugsBy
Eisai’s US ubsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, the US affiliate of Novartis AG, to collaborate on commercial and medical affairs activities (including the provision of scientific evidence to healthcare professionals) for Eisai’s in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) and Novartis’ anticancer agent, everolimus, in the United States. Each company will continue to book sales of their respective product.
Lenvima is approved for thyroid cancer in over 40 countries including the United States, Japan, in Europe, South Korea and Canada. Lenvima is also approved in combination with everolimus for patients with advanced renal cell carcinoma in the United States.n May 2016, Eisai received approval from the US Food and Drug Administration for the additional indication for Lenvima in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy in May 2016.
A new drug application seeking approval for an indication covering advanced or metastatic renal cell carcinoma submitted in Europe in January 2016 is under review, and Eisai intends to discuss further steps regarding submission strategies for this potential indication with the regulatory authorities in Japan.